Company intelligence / Profile preview

neuroaxpharm

Mississauga, Ontario, Canada

Ownership: Private
Development stage: Other

Overview

NeuroAxon was a clinical-stage biotechnology company focused on the development of next-generation pain therapeutics. The company's primary focus was on the discovery and development of selective inhibitors of neuronal nitric oxide synthase (nNOS), an enzyme implicated in the transmission of pain signals. Its lead candidate, NXN-188, was evaluated in Phase 2 clinical trials for the treatment of acute migraine and other pain conditions. Despite promising early data, the company faced challenges in later-stage development and eventually ceased operations, with its intellectual property being liquidated or licensed.

Therapeutic areas: Neurology
Modalities: Small molecule
Industry: Biotech

Partnerships

Vernalis

Beyond the preview

Go deeper on neuroaxpharm.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on neuroaxpharm.

Explore the full profile